Merck (MRK) Ticks Higher Following Positive Odanacatib Phase III News
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $131.07 +0.45%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +3.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.9%
Revenue Growth %: +3.8%
Join SI Premium – FREE
Merck & Co. (NYSE: MRK) shares are ticking higher in late trading Wednesday, following positive news for its investigational cathepsin K (cat-K) inhibitor, odanacatib.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
According to reports, odanacatib's Phase III is cleared for early cancellation by the DMC due to robust efficacy and a favorable benefit-risk profile.
Shares are about 3 percent higher late Wednesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck signs HIV prevention drug licenses covering 129 countries
- Tessera Therapeutics names former Merck executive as new CEO
- Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
